Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling.

d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. · 2017

Read Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. by d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5686520.txt.

Introduction

d'Hennezel and co-authors report a gut study in mSystems. It shows gut bacteria actively calm an immune alarm. A coat sugar called LPS covers many bacteria. It tends to spark alarm signals and swelling. The team took total LPS from healthy adult stool. Nine donors gave samples for the tests. Gene scans profiled the microbes in each sample.

The pooled gut LPS blocked the alarm path instead. It shut down Toll-like receptor 4 signaling. Tests used human immune cells and lab cell lines. Gene scans traced the effect to Bacteroidales members. These rule the healthy gut's Gram-negative group. Their LPS forms drive the calm for all gut microbes.

Catalog record

CREATORd'Hennezel E, Abubucker S, Murphy LO, Cullen TW.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5686520

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling By Eva d’Hennezel, Sahar Abubucker, Leon O Murphy, Thomas W Cullen, Catherine Lozupone Published in: mSystems DOI: 10.1128/mSystems.00046-17 ABSTRACT While the ability for humans to host a complex microbial ecosystem is an essential property of life, the mechanisms allowing for immune tolerance of such a large microbial load are not completely understood and are currently the focus of intense research. This study shows that an important proinflammatory pathway that is commonly triggered by pathogenic bacteria upon interaction with the host is, in fact, actively repressed by the bacteria of the gut microbiome, supporting the idea that beneficial microbes themselves contribute to the immune tolerance in support of homeostasis. These findings are important for two reasons. First, many currently assume that proinflammatory signaling by lipopolysaccharide is a fundamental feature of the gut flora. This assumption influences greatly how host-microbiome interactions are theoretically modeled but also how they are experimentally studied, by using robust TLR signaling conditions to simulate commensals. Second, elucidation of the mechanisms that support host-microbe tolerance is key to the development of therapeutics for both intestinal and systemic inflammatory disorders. KEYWORDS: microbiome, lipopolysaccharide, microbial communities, symbiosis, tolerance, Toll-like receptors INTRODUCTION The human gut microbiome comprises a large and dynamic population of microorganisms representing one of the most densely populated ecosystems known (1). This microbial consortium provides many benefits to its host, including key signals that shape gastrointestinal development, immune maturation, vitamin production, extraction of otherwise indigestible carbohydrates from the diet, and pathogen resistance (2). However, this presents the challenge for the host of containing, and remaining immunologically tolerant to, a microbial load in excess of 1012 cells/ml (1). Elaborate mechanisms are required to modulate and preserve this symbiotic relationship. To date, mechanisms reported to maintain this symbiosis rely on host-driven tolerance, including the physical barriers of the oriented epithelium and mucosa, secretion of antimicrobial peptides and secreted antibodies, or negative feedback loops in NF-κB signaling (3). Several mechanisms are also at play that contain both the risk of infection and the amplitude of the immune response (4). In recent years, studies have reported examples of microorganisms themselves promoting the expansion of Foxp3+ regulatory T cells (5, 6), the suppression of tumor necrosis factor alpha (TNF-α) production (7, 8), and the maintenance of the gut epithelium (9), suggesting that the microbiota could play a role in shaping host immune responses. However, specific microbiota-derived molecular mediators of host tolerance are still largely unknown. We recently reported that the commensal organism Bacteroides dorei produces an antagonistic form of lipopolysaccharide (LPS) that can influence the susceptibility of children to allergies and autoimmunity (10). While the ability of some LPS isoforms to inhibit Toll-like receptor 4 (TLR4) signaling has been reported (11), their broader implications with regard to gut health and disease remain unexamined. Here we directly extracted the total LPS from fecal samples from healthy adult humans and found that the LPS produced by the consortium of gut-resident microbes potently antagonizes the host TLR4 pathway. Using metagenomic sequencing, we further delineated strain level contributions to the gut LPS pool and found that numerous other members of the order Bacteroidales, which are the dominant Gram-negative bacteria in the healthy human gut microbiome (12), produce antagonistic forms of LPS, thus driving immune silencing for the entire microbial community. These findings undermine the current accepted paradigm that gut microbial communities possess a robust TLR4 signaling capacity against which the immune system needs to be heavily tolerized (13). Ours is the first report describing a phylum-wide microbiome-intrinsic mechanism actively damping innate immune activation in the healthy gut and redefines how we envision the immunological dynamics of the host-microbiota relationship. RESULTS Total LPS produced in the adult human gut is immunoinhibitory. Stool samples were collected from nine healthy adults and analyzed as illustrated in Fig. 1A. The microbial composition of each sample was analyzed by metagenomic whole-genome sequencing (WGS), which revealed an overall bacterial composition that was similar to the general microbial landscape depicted in Human Microbiome Project 1 (HMP1) (14) (Fig. 1B), suggesting that these samples are representative of the general population. [Figure: Total LPS from the human gut microbiome is immunoinhibitory. (A) Schematic diagram of sample processing and analysis in this study. (B) Principal-component analysis plot comparing the HMP1 sample set (blue) and a new set of nine healthy-donor (Novartis [NVS]) samples (black). (C) Human PBMCs were stimulated in the presence of increasing amounts of fecal LPS. IL-6 and IL-1β concentrations in supernatants were measured after 20 h of culture. E. coli LPS was included as a control. (D and E) HEK-293 cells expressing an NF-κB–luciferase reporter and either hTLR2 and hCD14 (D) or hTLR4, hMD2, and hCD14 (E) were stimulated in the presence of increasing doses of fecal LPS from each donor, B. dorei LPS, or E. coli PGN. A sterile-water negative control was included in each experiment (not shown). Luciferase activity was measured after 6 h of activation. Data shown are the mean ± the standard deviation of triplicate evaluations from one out of three independent experiments. (F) PBMCs were cotreated with 1 ng/ml E. coli LPS and increasing doses of fecal LPS from the donors indicated. IL-6 and IL-1β concentrations in supernatants were measured after 20 h of culture and compared to those obtained with LPS treatment alone (0:1). Data shown are the mean ± the standard deviation of triplicates in one representative experiment. *, corrected P value of <0.05.] LPS was purified from each donor as previously described (15) and further processed as previously described by Hirschfeld et al. to remove contaminating lipoproteins and yield purified LPS (16). The immunostimulatory potency of each sample of fecal LPS was then assessed by stimulating human primary PBMCs. The production of six inflammatory cytokines, interleukin-10 (IL-10), IL-6, IL-8, TNF-α, IL-12p70, and IL-1b, was measured in parallel. All cytokines that reached detectable levels (IL-10, IL-6, IL-8, IL-1b, and TNF-α) showed similar patterns of production, in accordance with their common regulation by NF-κB activation downstream of LPS. IL-6 and IL-1b are shown as representative results. All LPS samples showed ≥2 orders of magnitude lower stimulatory potency than purified Escherichia coli LPS (no. 1, 2, 5, 8, and 10), and many (no. 3, 4, 6, and 9) were immunologically silent up to the largest dose tested on primary peripheral blood mononuclear cells (PBMCs; 1 mg/ml) (Fig. 1C). Similar results were obtained when stimulating human TLR2 (hTLR2) and hTLR4--NF-κB reporter cell lines, confirming the absence of direct signaling through these LPS-sensing signaling pathways (Fig. 1D and E). Hence, total fecal LPS has a very limited capacity to activate the TLR4--NF-κB pathway and elicit the production of inflammatory cytokines. This result is particularly striking given that the gut microbiome is thought to elicit robust TLR4 signals and that total fecal LPS is likely derived from diverse microbial origins, including species known to produce potent forms of LPS (e.g., gammaproteobacteria). We further examined the immunomodulating properties of fecal LPS by cotreating PBMCs with fecal LPS prior to stimulation with E. coli LPS to assess their ability to interfere with immune stimulation. Fecal LPS from each donor potently inhibited the cytokine (IL-6, IL-1b) production elicited by E. coli LPS. Most fecal

Read the complete text